Molecular docking studies indicated strengthen the affinity of magnolol to the BACE-1 active site.<h4>Conclusion</h4>Nano-magnolol is promising in developing a new agent targeting cholinergic function, amyloidogenesis, neuro-inflammation, and oxidative stress reflecting its potent neuroprotective efficacy in AD treatment. This evidence concerns the gene BACE1 and Alzheimer disease.